---
title: "Drugs Made In America Acquisition II - Unit | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/266434256.md"
published_at: "2025-11-18T21:08:02.000Z"
---

# Drugs Made In America Acquisition II - Unit | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EBIT: As of FY2025 Q3, the actual value is USD -264.87 K.

### Segment Revenue

-   The company has not generated any operating revenues as of September 30, 2025, as it is a blank check company focused on identifying a target for a business combination.

### Operational Metrics

-   **Net Loss**: For the three months ended September 30, 2025, the net loss was $46,158, primarily due to general and administrative costs of $155,513, offset by interest income of $109,355. For the nine months ended September 30, 2025, the net loss was $143,558, with general and administrative costs totaling $252,913, offset by interest income of $109,355.

### Cash Flow

-   **Cash and Cash Equivalents**: As of September 30, 2025, the company had $315,087 in cash.
-   **Net Cash Used in Operating Activities**: For the nine months ended September 30, 2025, net cash used in operating activities was - $703,367.
-   **Net Cash Used in Investing Activities**: The company invested - $500,000,000 into a Trust Account.
-   **Net Cash Provided by Financing Activities**: The company generated $501,001,419 from financing activities, primarily from the Initial Public Offering and the sale of Private Placement Units.

### Unique Metrics

-   **Trust Account**: As of September 30, 2025, the cash and investments held in the Trust Account amounted to $500,109,355.

### Future Outlook and Strategy

-   **Core Business Focus**: The company intends to focus on acquiring businesses in the pharmaceutical industry. It plans to use the proceeds from its Initial Public Offering and Private Placement Units to consummate a business combination within 24 months from the IPO closing date.
-   **Non-Core Business**: There are no specific plans related to non-core business activities as the company is primarily focused on completing a business combination.
-   **Priority**: The company emphasizes completing a business combination within the specified timeframe to avoid liquidation and dissolution.

### Related Stocks

- [DMIIU.US - Drugs Made In America Acquisition II - Unit](https://longbridge.com/en/quote/DMIIU.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 網域存儲技術｜10-Q：2026 財年 Q3 營收 17.13 億美元超過預期 |  | [Link](https://longbridge.com/en/news/277098170.md) |
| 斯馬克｜10-Q：2026 財年 Q3 營收 23.39 億美元超過預期 |  | [Link](https://longbridge.com/en/news/277098786.md) |
| 易康公司｜10-K：2025 財年營收 5540 億美元超過預期 |  | [Link](https://longbridge.com/en/news/277098838.md) |
| Somnigroup｜10-K：2025 財年營收 74.77 億美元不及預期 |  | [Link](https://longbridge.com/en/news/277248576.md) |
| Capital City Bank｜10-K：2025 財年營收 2.87 億美元 |  | [Link](https://longbridge.com/en/news/277233794.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.